YJ1206, CAS [[3053716-98-3]]

Produktübersicht

• Artikelname: YJ1206, CAS [[3053716-98-3]]
• Artikelnummer: MCE-HY-168555
• Hersteller Artikelnummer: HY-168555
• Alternativnummer: MCE-HY-168555-25MG,MCE-HY-168555-500MG,MCE-HY-168555-10MG,MCE-HY-168555-1G,MCE-HY-168555-100MG,MCE-HY-168555-250MG,MCE-HY-168555-5MG,MCE-HY-168555-50MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien

Produktbeschreibung

YJ1206 is an orally active, selective CDK12/CDK13 PROTAC degrader with an IC50 of 12.55 nM for in VCaP cells. YJ1206 increases DNA damage, induces apoptosis, and promotes tumor regression in orthotopic WA74 patient-derived xenograft (PDX) mice models of resistant prostate cancer. YJ1206 suppresses tumor growth in vivo in conjunction with AKT pathway inhibitors. YJ1206 is composed of the CDK12/CDK13 degradation agent (HY-168658), a linker (HY-W004328), and a VHL E3 ubiquitin ligase (HY-W453548). (Pink: Navitoclax, Blue: VHL ligand, Black: linker)[1].

Produkteigenschaften

• Molekulargewicht: 894.01
• Reinheit: 96.92
• CAS Nummer: [3053716-98-3]
• Formel: C49H52FN11O5
• Target-Kategorie: Apoptosis,CDK,PROTACs

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Reference compound